ES2184865T3 - Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo. - Google Patents

Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo.

Info

Publication number
ES2184865T3
ES2184865T3 ES96916354T ES96916354T ES2184865T3 ES 2184865 T3 ES2184865 T3 ES 2184865T3 ES 96916354 T ES96916354 T ES 96916354T ES 96916354 T ES96916354 T ES 96916354T ES 2184865 T3 ES2184865 T3 ES 2184865T3
Authority
ES
Spain
Prior art keywords
peptide
blood
triglicerids
level
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916354T
Other languages
English (en)
Inventor
Kyoichi Kagawa
Hisako Matsutaka
Chizuko Fukuhama
Hiroaki Fujino
Masahiro Numata
Kazuhisa Honda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hankyo Kyoei Bussan Co Ltd
Original Assignee
Hankyo Kyoei Bussan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hankyo Kyoei Bussan Co Ltd filed Critical Hankyo Kyoei Bussan Co Ltd
Application granted granted Critical
Publication of ES2184865T3 publication Critical patent/ES2184865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UN PEPTIDO QUE PRESENTA UNA SECUENCIA DE AMINOACIDOS DE VAL - VAL - TYR - PRO, ASI COMO DE UN AGENTE PARA INHIBIR LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, DE UN ALIMENTO PARA UN USO EN SALUD ESPECIFICADO (LOS LLAMADOS ALIMENTOS FISIOLOGICAMENTE FUNCIONALES) Y DE UN PIENSO QUE INCLUYE EL ANTERIOR PEPTIDO COMO COMPONENTE ACTIVO. SEGUN LA PRESENTE INVENCION, SE OBTIENE UN PEPTIDO QUE INHIBE LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, ASI COMO UN AGENTE PARA INHIBIR LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, UN ALIMENTO FISIOLOGICAMENTE FUNCIONAL Y UN PIENSO, INCLUYENDO TODOS ELLOS EL PEPTIDO COMO COMPONENTE ACTIVO. CON ESTOS PRODUCTOS DE LA INVENCION, RESULTA POSIBLE PREVENIR O TRATAR LA OBESIDAD Y LA HIPERLIPEMIA EN HUMANOS Y ANIMALES, ASI COMO ENFERMEDADES DEL SISTEMA CIRCULATORIO, TAL COMO LA HIPERTENSION Y LA ARTERIOESCLEROSIS ASOCIADA A ELLA. ADEMAS, LOS MATERIALES DE LA INVENCION POSIBILITAN LA MEJORA DE LA CALIDAD DELA CARNE DE GANADO Y DE PECES DE VIVERO.
ES96916354T 1996-03-22 1996-06-10 Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo. Expired - Lifetime ES2184865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8066916A JP2805194B2 (ja) 1996-03-22 1996-03-22 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤

Publications (1)

Publication Number Publication Date
ES2184865T3 true ES2184865T3 (es) 2003-04-16

Family

ID=13329785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916354T Expired - Lifetime ES2184865T3 (es) 1996-03-22 1996-06-10 Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo.

Country Status (11)

Country Link
US (1) US5958885A (es)
EP (1) EP0838473B1 (es)
JP (1) JP2805194B2 (es)
KR (1) KR100264344B1 (es)
AT (1) ATE225803T1 (es)
AU (1) AU690853B2 (es)
CA (1) CA2221767C (es)
DK (1) DK0838473T3 (es)
ES (1) ES2184865T3 (es)
NO (1) NO325836B1 (es)
WO (1) WO1997035875A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095794A (ja) * 1998-09-22 2000-04-04 Itoham Foods Inc エンケファリン分解酵素の阻害剤
JP2000264845A (ja) * 1999-02-04 2000-09-26 Nippon Synthetic Chem Ind Co Ltd:The コレステロール降下剤及びその用途
US7060467B2 (en) 2000-03-13 2006-06-13 Monsanto Technology Llc Recombinant proteins containing repeating units
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
WO2003092614A2 (en) * 2002-05-02 2003-11-13 Hickle Randall S Lipid removal from the body
GB0211849D0 (en) * 2002-05-23 2002-07-03 Mok Kenneth H Improvments to retro-inverso isomers
NO322425B1 (no) * 2003-07-04 2006-10-02 Berge Biomed As Anvendelse av et hydrolysat av proteinholdig fiskemateriale for fremstilling av et farmasoytisk middel for behandling og/eller hindring av patologisk hoye nivaer av tracylglyceroler, hyperkolesterolemia, hyperhomocysteinemia, eller patologisk lave nivaer av beta-oksidasjon i et dyr eller menneske.
WO2006038327A1 (ja) * 2004-09-30 2006-04-13 Suntory Limited グロビン蛋白分解物を含有する酵母発酵飲料
WO2006052031A1 (en) * 2004-11-15 2006-05-18 Mg Pharma Inc. Protein hydrolysate with antidiabetic effect
JP4395658B2 (ja) 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
JP5175484B2 (ja) * 2007-03-30 2013-04-03 名古屋製酪株式会社 血中中性脂肪濃度上昇抑制剤
CA2695666C (en) * 2007-08-07 2016-05-17 Mg Pharma Inc. Anti-hypertensive agent
WO2018001273A1 (zh) * 2016-06-30 2018-01-04 江西本草天工科技有限责任公司 肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途
CN107556363B (zh) * 2016-06-30 2021-03-30 江西本草天工科技有限责任公司 肽或其盐及其制备方法
CN107551258B (zh) * 2016-06-30 2021-01-05 江西本草天工科技有限责任公司 用于预防和/或治疗肝损伤的vvyp

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723443A (en) * 1988-02-02 1998-03-03 Hankyu-Kyoei Bussan Co. Ltd. Lipid metabolism promoting agent and its use
CA1335567C (en) * 1988-02-02 1995-05-16 Kyoichi Kagawa Lipid metabolism promoting agent
JP2764276B2 (ja) * 1988-09-06 1998-06-11 仙味エキス株式会社 機能性新規ペプチド及びその利用
JPH0331298A (ja) * 1989-06-28 1991-02-12 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
JPH03120224A (ja) * 1989-10-04 1991-05-22 Ajinomoto Co Inc 新規ペプチドおよびこれを含有する降圧剤
JP3312944B2 (ja) * 1993-03-24 2002-08-12 伊藤ハム株式会社 脂肪細胞分化抑制ペプチド及び当該ペプチドを有効成分とする脂肪細胞分化抑制剤
JP2800877B2 (ja) * 1993-12-28 1998-09-21 伊藤ハム株式会社 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤

Also Published As

Publication number Publication date
EP0838473A1 (en) 1998-04-29
ATE225803T1 (de) 2002-10-15
AU690853B2 (en) 1998-04-30
AU5912096A (en) 1997-10-17
DK0838473T3 (da) 2003-02-17
NO325836B1 (no) 2008-07-28
US5958885A (en) 1999-09-28
WO1997035875A1 (fr) 1997-10-02
NO975360L (no) 1998-01-21
CA2221767C (en) 2001-01-23
JP2805194B2 (ja) 1998-09-30
EP0838473A4 (en) 2000-04-05
CA2221767A1 (en) 1997-10-02
NO975360D0 (no) 1997-11-21
KR100264344B1 (ko) 2000-08-16
KR19990021880A (ko) 1999-03-25
JPH09255698A (ja) 1997-09-30
EP0838473B1 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
ES2184865T3 (es) Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo.
Sørensen et al. Effects of age and stocking density on leg weakness in broiler chickens
Stafford et al. Dehorning and disbudding distress and its alleviation in calves
Su et al. A note on the effects of perches and litter substrate on leg weakness in broiler chickens
BRPI0413079A (pt) composição veterinária mastigável dútil saborosa
ES2153415T3 (es) Peptido inhibidor de la diferenciacion de adipocitos e inhibidor de la diferenciacion de adipocitos que contiene dicho peptido como ingrediente activo.
BR9408019A (pt) Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
BR0013879A (pt) Melhoria da condição de saúde de animais de estimação de idade avançada
PT1011723E (pt) Factor de crescimento tumorigenico de 88 kda e antagonistas
Croom et al. Neuropeptide Y, peptide YY and aluminum in Alzheimer’s disease:: Is there an etiological relationship?
Vaughan Flexural deformity of the carpus in puppies
Firth et al. Effects of racetrack exercise on third metacarpal and carpal bone of New Zealand thoroughbred horses
FI974601A (fi) Veren triglyseriditason kohoamista estävä peptidi ja mainittua peptidiä aktiivisena aineosana sisältävä veren triglyseriditason kohoamisen estäjä
RU2314111C1 (ru) Способ профилактики транспортного стресса крупного рогатого скота
Reiter et al. Effect of reduced weight load on locomotor activity and leg disorders in broiler chickens
ATE152879T1 (de) Antiparasitäre zusammensetzung zur verwendung bei tieren
Walsh Laminitis treatment: A personal memoir
Yardımcı et al. Surgical management of ectrodactyly in a Turkish Kangal dog
Lloyd-Bauer et al. Correction of acquired flexural deformity by deep digital flexor tenotomy in a miniature horse
Conklin Mechanical objectives: simplifying the approach to equine podiatry.
Jansson et al. Acquired flexural deformity of the distalinterphalangeal joint in horses: Treatment by desmotomy of the accessory ligament of the deep digital flexor tendon: A retrospective study
Shivaprakash et al. Incidence and management of congenital malformations of muscular system and limbs
Arnbjerg Changes in the distal phalanx in foals with deep digital flexor tendon contraction
Raghuvanshi et al. Resolution of equine lameless: management of the equine foot, based on its anatomy and function.
CA2225412A1 (en) A peptide inhibiting elevations of triglyceride levels in blood and an agent for inhibiting elevations of triglyceride levels in blood comprising the peptide as an active component